Multivariate Cox model for study cohorts undergoing HCT for MPN-BP vs post-MDS AML
| . | n . | HR (95% CI) . | P . |
|---|---|---|---|
| aGVHD II-IV | |||
| MDS-AML | 1090 | 1.00 (Reference) | .98 |
| MPN-BP | 176 | 1.00 (0.79-1.27) | |
| aGVHD III-IV | |||
| MDS-AML | 1086 | 1.00 (Reference) | .94 |
| MPN-BP | 174 | 0.99 (0.69-1.41) | |
| cGVHD | |||
| MDS-AML | 1091 | 1.00 (Reference) | .32 |
| MPN-BP | 176 | 0.88 (0.67-1.14) | |
| OS | |||
| Post-MDS AML | 1104 | 1.00 (Reference) | .05 |
| MPN-BP | 177 | 1.19 (1.00-1.43) | |
| Relapse | |||
| Post-MDS AML | 1085 | 1.00 (Reference) | <.0001 |
| MPN-BP | 177 | 1.60 (1.31-1.96) | |
| NRM | |||
| Post-MDS AML | 1085 | 1.00 (Reference) | .81 |
| MPN-BP | 177 | 0.96 (0.69-1.34) | |
| PFS | |||
| Post-MDS AML | 1085 | 1.00 (Reference) | .0003 |
| MPN-BP | 177 | 1.38 (1.16-1.63) |
| . | n . | HR (95% CI) . | P . |
|---|---|---|---|
| aGVHD II-IV | |||
| MDS-AML | 1090 | 1.00 (Reference) | .98 |
| MPN-BP | 176 | 1.00 (0.79-1.27) | |
| aGVHD III-IV | |||
| MDS-AML | 1086 | 1.00 (Reference) | .94 |
| MPN-BP | 174 | 0.99 (0.69-1.41) | |
| cGVHD | |||
| MDS-AML | 1091 | 1.00 (Reference) | .32 |
| MPN-BP | 176 | 0.88 (0.67-1.14) | |
| OS | |||
| Post-MDS AML | 1104 | 1.00 (Reference) | .05 |
| MPN-BP | 177 | 1.19 (1.00-1.43) | |
| Relapse | |||
| Post-MDS AML | 1085 | 1.00 (Reference) | <.0001 |
| MPN-BP | 177 | 1.60 (1.31-1.96) | |
| NRM | |||
| Post-MDS AML | 1085 | 1.00 (Reference) | .81 |
| MPN-BP | 177 | 0.96 (0.69-1.34) | |
| PFS | |||
| Post-MDS AML | 1085 | 1.00 (Reference) | .0003 |
| MPN-BP | 177 | 1.38 (1.16-1.63) |